AR105142A1 - Métodos de tratamiento del glioblastoma multiforme con terapia de células t - Google Patents

Métodos de tratamiento del glioblastoma multiforme con terapia de células t

Info

Publication number
AR105142A1
AR105142A1 ARP160101927A ARP160101927A AR105142A1 AR 105142 A1 AR105142 A1 AR 105142A1 AR P160101927 A ARP160101927 A AR P160101927A AR P160101927 A ARP160101927 A AR P160101927A AR 105142 A1 AR105142 A1 AR 105142A1
Authority
AR
Argentina
Prior art keywords
treatment methods
cell therapy
multiform glioblastoma
multiform
glioblastoma
Prior art date
Application number
ARP160101927A
Other languages
English (en)
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AR105142A1 publication Critical patent/AR105142A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

Métodos para tratar el glioblastoma multiforme (GBM) en un paciente humano que lo necesita, que comprende administrar al paciente humano una población de células T alogénicas que comprenden células T específicas para CMV (citomegalovirus).
ARP160101927A 2015-06-27 2016-06-24 Métodos de tratamiento del glioblastoma multiforme con terapia de células t AR105142A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562185563P 2015-06-27 2015-06-27

Publications (1)

Publication Number Publication Date
AR105142A1 true AR105142A1 (es) 2017-09-06

Family

ID=56404299

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101927A AR105142A1 (es) 2015-06-27 2016-06-24 Métodos de tratamiento del glioblastoma multiforme con terapia de células t

Country Status (3)

Country Link
US (1) US20160375060A1 (es)
AR (1) AR105142A1 (es)
WO (1) WO2017003763A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3294304B1 (en) * 2015-05-12 2020-01-29 Memorial Sloan Kettering Cancer Center Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy
CN107921065A (zh) * 2015-06-26 2018-04-17 纪念斯隆-凯特林癌症中心 通过t细胞疗法治疗cmv视网膜炎的方法

Also Published As

Publication number Publication date
US20160375060A1 (en) 2016-12-29
WO2017003763A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
CO2017011197A2 (es) Terapia de combinación fgfr/pd-1 para el tratamiento del cancer
CL2017003006A1 (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
SV2017005489A (es) Terapias de combinación para el tratamiento de cánceres
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
MY187540A (en) Compounds active towards bromodomains
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MY189857A (en) Methods of selecting t cell line and donor thereof for adoptive cellular therapy
CO7200273A2 (es) Combinaciones farmaceúticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
NI201500150A (es) TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método
MX370953B (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
AR104598A1 (es) Métodos para tratar trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
GB2554591A (en) Clinical support system and method
PH12015502266A1 (en) Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
PH12020550185A1 (en) Semaglutide in medical therapy
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
AR105142A1 (es) Métodos de tratamiento del glioblastoma multiforme con terapia de células t
EA201692164A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
MX2017001512A (es) Compuestos activos hacia bromodominios.

Legal Events

Date Code Title Description
FB Suspension of granting procedure